Genentech Reports Positive Phase III Interim for Sefaxersen in IgAN

Genentech Reports Positive Phase III Interim for Sefaxersen in IgAN

Less than 1 min read

Genentech said Phase III IMAgINATION met its primary endpoint, with sefaxersen significantly reducing proteinuria vs placebo at 37 weeks in IgA nephropathy. Safety was consistent with prior data; the blinded study continues to week 105 for eGFR.

Material Details

| # | Detail | AI Analyst View |

|---|---|---|

| 1 | Phase III primary endpoint met | De-risks the asset; increases probability of approval and future revenue. |

| 2 | Significant UPCR reduction at 37 weeks | Proteinuria is a validated surrogate tied to kidney outcomes; supports efficacy. |

| 3 | No new safety signals | Clean safety reduces regulatory risk and broadens potential use. |

| 4 | Once-monthly SC, self-admin | Convenience can aid uptake and adherence, supporting commercial adoption. |

| 5 | eGFR endpoint reads at week 105 | Harder outcome needed for labeling and payer support; key next catalyst. |

| 6 | Interim data to regulators | Opens path to discussions on potential expedited pathways or filing. |

Context by AI Analyst

This is a mid-to-late development milestone, offering clinical validation for a key renal asset licensed...